OverviewSuggest Edit

Athenex is a biopharmaceutical company dedicated to the discovery and commercialization of therapies for the treatment of cancer. It operates medical technology innovation centers and a manufacturing supply chain. The company delivers proprietary medical technologies, including small molecule, biologic, and cellular therapies.
TypePublic
Founded2003
Websiteathenex.com

Latest Updates

Employees (est.) (Dec 2018)575
Job Openings27
Share Price (Mar 2020)$7.5 (-12%)

Key People/Management at Athenex

Johnson Y.n. Lau

Johnson Y.n. Lau

Chief Executive Officer and Board Chairman, Director
Rudolf Kwan

Rudolf Kwan

Chief Medical Officer
Kim Campbell

Kim Campbell

Lead Independent Director
Simon Pedder

Simon Pedder

Chief Business and Strategy Officer, Proprietary Products
Stephanie Davis

Stephanie Davis

Director
Randoll Sze

Randoll Sze

Chief Financial Officer
Show more

Athenex Financials and Metrics

Athenex Revenue

Market capitalization (27-Mar-2020)

614.7m

Closing stock price (27-Mar-2020)

7.5
Athenex's current market capitalization is $614.7 m.
Show all financial metrics

Athenex Online and Social Media Presence

Embed Graph

Athenex Frequently Asked Questions

  • When was Athenex founded?

    Athenex was founded in 2003.

  • Who are Athenex key executives?

    Athenex's key executives are Johnson Y.n. Lau, Rudolf Kwan and Kim Campbell.

  • How many employees does Athenex have?

    Athenex has 575 employees.

  • Who are Athenex competitors?

    Competitors of Athenex include ImmunSYS, Precision Medicines and NOXXON Pharma.